What pattern of hepatotoxicity is associated with tigecycline?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Pattern of Hepatotoxicity with Tigecycline

Tigecycline causes primarily elevated liver function tests (transaminases and bilirubin) with a mixed hepatocellular-cholestatic pattern, though cholestatic injury predominates in clinical practice. 1

Hepatotoxicity Pattern Classification

The FDA drug label explicitly states that tigecycline causes increases in total bilirubin concentration, prothrombin time, and transaminases 1. When classified by the R-value system (ALT/ULN ÷ ALP/ULN), tigecycline-associated liver injury manifests across patterns:

Pattern Distribution from Clinical Data

A 2021 Chinese retrospective study of 973 patients found tigecycline-associated DILI occurred in 5.7% of patients, with the following pattern breakdown 2:

  • Cholestatic pattern: 74.5% (41/55 cases) - most common
  • Hepatocellular pattern: 18.2% (10/55 cases)
  • Mixed pattern: 7.3% (4/55 cases)

This cholestatic predominance is further supported by pharmacovigilance data showing tigecycline had the strongest association with cholestatic injury (ROR 12.16,95% CI 10.13-14.61) compared to other tetracyclines 3.

Severity and Clinical Presentation

Most cases are mild to moderate (Grade 1-2 severity), though isolated cases of significant hepatic dysfunction and hepatic failure have been reported 1. The British Thoracic Society guidelines list "elevated LFTs" as a common adverse effect 4.

Recovery Rates by Pattern

Recovery rates vary by injury pattern 2:

  • Hepatocellular: 70.0% recovery
  • Mixed: 50.0% recovery
  • Cholestatic: 41.5% recovery (poorest prognosis)

Timing of Onset

Hepatotoxicity typically develops early in treatment. A 2026 Chinese ICU study found 5:

  • Median time to DILI onset: 4 days among affected patients
  • Kaplan-Meier median DILI-free survival: 18 days in the full cohort

This early onset pattern necessitates hepatic monitoring from treatment initiation.

Dose-Response Relationship

Higher cumulative doses and prolonged duration significantly increase hepatotoxicity risk. Multiple studies demonstrate this relationship:

A 2026 study identified serum concentration thresholds predictive of hepatotoxicity 6:

  • Trough concentration (Cmin) threshold: 0.535 mg/L
  • 6-hour post-dose concentration (C6h) threshold: 0.690 mg/L

The 2021 Chinese study found 100% of DILI cases received high-dose tigecycline (100 mg maintenance) versus only 18.1% of non-DILI patients 2. Independent risk factors included:

  • High maintenance dose (OR = 1.028, p = 0.002)
  • Prolonged duration >14 days (OR = 1.208, p < 0.001)
  • Total duration per week (OR = 2.01,95% CI: 1.42-2.92) 5
  • Cumulative dose per gram (OR = 1.51,95% CI: 1.19-1.94) 5

Critical Clinical Considerations

Hepatic dysfunction may occur after drug discontinuation 1, requiring continued monitoring post-treatment. The FDA label warns that patients who develop abnormal liver function tests should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing therapy.

High-Risk Populations

Tigecycline should be used cautiously in patients with liver insufficiency 7. The 2023 carbapenem-resistant guidelines specifically note: "tigecycline should be used cautiously in patients with liver insufficiency" 7.

Concomitant Hepatotoxic Drugs

Number of hepatotoxic drugs is an independent risk factor (OR = 2.232, p < 0.001) 2. A 2026 study identified concomitant use of voriconazole or statins as significantly associated with increased hepatotoxicity risk 6.

Monitoring Recommendations

Based on the early onset pattern and dose-dependent relationship:

  • Baseline liver function tests required
  • Monitor LFTs closely during first week (median onset 4 days)
  • Continue monitoring throughout therapy, especially beyond 14 days
  • Consider therapeutic drug monitoring in high-risk patients, targeting Cmin <0.535 mg/L and C6h <0.690 mg/L 6
  • Extended surveillance post-discontinuation given potential for delayed hepatic dysfunction 1

The cholestatic-predominant pattern with relatively poor recovery rates (41.5%) underscores the importance of early detection and prompt discontinuation when hepatotoxicity develops.

References

Related Questions

What are the monitoring requirements for lymecycline (tetracycline antibiotic)?
In a patient with necrotising fasciitis receiving tigecycline and clindamycin who develops abdominal pain and an elevated serum lipase (277 U/L), how should the presumed drug‑induced pancreatitis be managed and what alternative antimicrobial regimen should be used?
What is the recommended treatment for Tourette syndrome co-occurring with attention-deficit/hyperactivity disorder (ADHD)?
What are the recommended treatment options for COVID‑19, including antiviral therapy, supportive care, and management for mild and severe disease?
What kind of precautions should be implemented for a patient with suspected or confirmed COVID‑19?
In a patient with acute ischemic stroke who was started on aspirin 300 mg and MRI shows a small hemorrhagic transformation, how should antiplatelet therapy be managed?
What are the laboratory and clinical markers of fulminant hepatic injury?
What is the diagnostic approach for Wilson disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.